We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Expression of vasohibin‑1 and ‑2 predicts poor prognosis among patients with squamous cell carcinoma of the esophagus.
- Authors
Ninomiya, Yamato; Ozawa, Soji; Oguma, Junya; Kazuno, Akihito; Nitta, Miho; Kajiwara, Hiroshi; Sato, Yasufumi
- Abstract
Vasohibin (VASH) ‑1 and ‑2 are novel angiogenic regulators. The aim of the present study was to assess the prognostic values of VASH1 expression and VASH2 expression in esophageal squamous cell carcinoma (ESCC). A total of 209 patients with ESCC were investigated. Resected tumor specimens were immunostained using anti‑CD34 antibody, anti‑VASH1 antibody and anti‑VASH2 antibody. The ratio of the microvessels density and the VASH1 density as the VASH1‑positive ratio were defined and the patients were divided into two groups (a high VASH1 group and a low VASH1 group) according to the average value. The patients were also divided into two groups (a high VASH2 group and a low VASH2 group) according to VASH2 expression upon immunostaining. The clinical outcomes of these two groups were then evaluated. The high VASH1 group contained 106 patients (50.7%). The high VASH2 group contained 48 patients (23.0%). Long‑term survival was significantly poorer in the high VASH1 group compared with that in the low VASH1 group. A slight correlation between VASH1 expression and VASH2 expression was observed. The low VASH1/low VASH2 group had a better prognosis than the other three groups with different combinations of VASH1 and VASH2 expression levels. The present study showed that high VASH1 expression and high VASH2 expression may be novel independent predictors of a poor prognosis in patients with ESCC and that a slight correlation between VASH1 and VASH2 expression existed. The present findings suggest that combined evaluation of VASH1 and VASH2 expression should provide an improved understanding of their clinicopathological features.
- Subjects
PROTEIN expression; SQUAMOUS cell carcinoma; ANTI-antibodies; IMMUNOSTAINING; STATISTICAL correlation; PROGNOSIS
- Publication
Oncology Letters, 2018, Vol 16, Issue 4, p5265
- ISSN
1792-1074
- Publication type
Article
- DOI
10.3892/ol.2018.9249